Why Resmed's 63% gain looks small

This company could give investors outstanding returns in the long run.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Resmed's (ASX: RMD) stellar run for the last financial year has highlighted it as one of the most promising developers and manufacturers of medical products on the market.

Resmed's purpose is to develope products for the treatment and management of respiratory disorders, with a key focus on sleep apnea – an increasingly common sleep disorder. Whilst the company has solidified its position as a global leader in its industry, it has delivered outstanding results throughout FY12. For the nine months ending March 31, it recognised an incredible $1.1 billion in revenue, measuring 10% greater than the revenue recognised in the nine months ending March 31 of the previous year.

Meanwhile, the company also increased its research and development costs by 8.4%, which is a pleasing sign, showing that it is  working towards developing market-beating products to drive growth well into the future.

Over the financial year, Resmed gave investors a solid 63% return to finish on $5 per share. It has now fallen away marginally to around $4.90, however, stockbroking firm Bell Potter has set its target at $6.00.

Whilst Bell Potter's outlook on the company is certainly encouraging, it is the long-term potential that Resmed holds that should attract investors. In the long-term, it looks like this company could be worth much more than just $6 as more and more people seek treatment for common respiratory disorders.

Foolish takeaway

Although there are certainly risks involved in investing in this sector, as shareholders in companies such as Pharmaxis (ASX: PXS) would tell you, there are also a number of other Australian companies that have made their impact. Cochlear implantable device manufacturer Cochlear (ASX: COH) and biotechnology group Sirtex Medical (ASX: SRX) are global leaders in their respective fields, and also present as fantastic long-term prospects.

The Australian Financial Review says "good quality Australian shares that have a long history of paying dividends are a real alternative to a term deposit." Get "3 Stocks for the Great Dividend Boom" in our special FREE report. Click here now to find out the names, stock symbols, and full research for our three favourite income ideas, all completely free!

More reading


Motley Fool contributor Ryan Newman does not own shares in any of the companies mentioned in this article.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »